198 related articles for article (PubMed ID: 29273955)
21. The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status.
Glajcar A; Szpor J; Hodorowicz-Zaniewska D; Tyrak KE; Okoń K
Virchows Arch; 2019 Jul; 475(1):13-23. PubMed ID: 31016433
[TBL] [Abstract][Full Text] [Related]
22. Altered expression of HLA class I antigens in breast cancer: association with prognosis.
Gudmundsdóttir I; Gunnlaugur Jónasson J; Sigurdsson H; Olafsdóttir K; Tryggvadóttir L; Ogmundsdóttir HM
Int J Cancer; 2000 Nov; 89(6):500-5. PubMed ID: 11102894
[TBL] [Abstract][Full Text] [Related]
23. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.
Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J
J Cell Mol Med; 2020 Mar; 24(5):2993-3021. PubMed ID: 31989747
[TBL] [Abstract][Full Text] [Related]
24. The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma.
Talebian Yazdi M; van Riet S; van Schadewijk A; Fiocco M; van Hall T; Taube C; Hiemstra PS; van der Burg SH
Oncotarget; 2016 Jan; 7(3):3477-88. PubMed ID: 26658106
[TBL] [Abstract][Full Text] [Related]
25. The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators.
Georgiannos SN; Renaut A; Goode AW; Sheaff M
Surgery; 2003 Nov; 134(5):827-34. PubMed ID: 14639362
[TBL] [Abstract][Full Text] [Related]
26. The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer.
Gujam FJ; Edwards J; Mohammed ZM; Going JJ; McMillan DC
Br J Cancer; 2014 Jul; 111(1):157-65. PubMed ID: 24874480
[TBL] [Abstract][Full Text] [Related]
27. Transglutaminase 2 overexpression in tumor stroma identifies invasive ductal carcinomas of breast at high risk of recurrence.
Assi J; Srivastava G; Matta A; Chang MC; Walfish PG; Ralhan R
PLoS One; 2013; 8(9):e74437. PubMed ID: 24058567
[TBL] [Abstract][Full Text] [Related]
28. Prognostic evaluation of tumor-stroma ratio in patients with early stage cervical adenocarcinoma treated by surgery.
Pongsuvareeyakul T; Khunamornpong S; Settakorn J; Sukpan K; Suprasert P; Intaraphet S; Siriaunkgul S
Asian Pac J Cancer Prev; 2015; 16(10):4363-8. PubMed ID: 26028100
[TBL] [Abstract][Full Text] [Related]
29. Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression.
Stenström J; Hedenfalk I; Hagerling C
Breast Cancer Res; 2021 Feb; 23(1):27. PubMed ID: 33602289
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological correlation of tumor-stroma ratio and inflammatory cell infiltrate with tumor grade and lymph node metastasis in squamous cell carcinoma of buccal mucosa and tongue in 41 cases with review of literature.
Rani P; Gupta AJ; Mehrol C; Singh M; Khurana N; Passey JC
J Cancer Res Ther; 2020; 16(3):445-451. PubMed ID: 32719249
[TBL] [Abstract][Full Text] [Related]
31. Proposal of an automated tumor-stromal ratio assessment algorithm and a nomogram for prognosis in early-stage invasive breast cancer.
Xu Q; Chen YY; Luo YH; Zheng JS; Lin ZH; Xiong B; Wang LW
Cancer Med; 2023 Jan; 12(1):131-145. PubMed ID: 35689454
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of tumor-stroma ratio in oral carcinoma: Role of cancer-associated fibroblasts.
Qiu J; Jiang E; Shang Z
Oral Dis; 2023 Jul; 29(5):1967-1978. PubMed ID: 35388593
[TBL] [Abstract][Full Text] [Related]
33. NK Cell Infiltrates and HLA Class I Expression in Primary HER2
Muntasell A; Rojo F; Servitja S; Rubio-Perez C; Cabo M; Tamborero D; Costa-García M; Martínez-Garcia M; Menéndez S; Vazquez I; Lluch A; Gonzalez-Perez A; Rovira A; López-Botet M; Albanell J
Clin Cancer Res; 2019 Mar; 25(5):1535-1545. PubMed ID: 30523021
[TBL] [Abstract][Full Text] [Related]
34. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence.
Suzuki K; Kadota K; Sima CS; Nitadori J; Rusch VW; Travis WD; Sadelain M; Adusumilli PS
J Clin Oncol; 2013 Feb; 31(4):490-8. PubMed ID: 23269987
[TBL] [Abstract][Full Text] [Related]
35. The prognostic significance of tumor-associated stroma in invasive breast carcinoma.
Ahn S; Cho J; Sung J; Lee JE; Nam SJ; Kim KM; Cho EY
Tumour Biol; 2012 Oct; 33(5):1573-80. PubMed ID: 22581521
[TBL] [Abstract][Full Text] [Related]
36. A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer.
Flores-Martín JF; Perea F; Exposito-Ruiz M; Carretero FJ; Rodriguez T; Villamediana M; Ruiz-Cabello F; Garrido F; Cózar-Olmo JM; Aptsiauri N
Ann Surg Oncol; 2019 Aug; 26(8):2631-2639. PubMed ID: 31011905
[TBL] [Abstract][Full Text] [Related]
37. Peripheral blood immune markers in breast cancer: Differences in regulatory T cell abundance are related to clinical parameters.
Jørgensen N; Lænkholm AV; Sækmose SG; Hansen LB; Hviid TVF
Clin Immunol; 2021 Nov; 232():108847. PubMed ID: 34506945
[TBL] [Abstract][Full Text] [Related]
38. Clinical implication of HLA class I expression in breast cancer.
Kaneko K; Ishigami S; Kijima Y; Funasako Y; Hirata M; Okumura H; Shinchi H; Koriyama C; Ueno S; Yoshinaka H; Natsugoe S
BMC Cancer; 2011 Oct; 11():454. PubMed ID: 22014037
[TBL] [Abstract][Full Text] [Related]
39. Association between tumor-stroma ratio and prognosis in solid tumor patients: a systematic review and meta-analysis.
Wu J; Liang C; Chen M; Su W
Oncotarget; 2016 Oct; 7(42):68954-68965. PubMed ID: 27661111
[TBL] [Abstract][Full Text] [Related]
40. Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients?
Jordanova ES; Gorter A; Ayachi O; Prins F; Durrant LG; Kenter GG; van der Burg SH; Fleuren GJ
Clin Cancer Res; 2008 Apr; 14(7):2028-35. PubMed ID: 18381941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
